Xarelto is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, and Bayer AG [1][2].
What is the generic name for Xarelto?
The generic name for Xarelto is rivaroxaban [3].
When does the patent for Xarelto expire?
The patent expiry for Xarelto varies by region and specific patent. For instance, in the United States, primary patents related to rivaroxaban have faced challenges and some have expired or are nearing expiration, with the potential for generic versions to emerge [4][5]. DrugPatentWatch.com tracks these patent expiries and provides detailed information on specific patents and their timelines [4].
Are there other blood thinners like Xarelto?
Yes, there are other anticoagulant medications. These include other direct oral anticoagulants (DOACs) such as Eliquis (apixaban), Savaysa (edoxaban), and Pradaxa (dabigatran etexilate). Older anticoagulants like warfarin are also still in use [6].
Who else makes generic versions of rivaroxaban?
As patents expire or are challenged, other pharmaceutical companies may begin manufacturing generic versions of rivaroxaban. Information regarding specific manufacturers of generic rivaroxaban is typically available as approvals are granted by regulatory bodies and products enter the market [4].
What are the risks associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is an increased risk of bleeding. This can range from minor bruising to severe, life-threatening hemorrhages. Other potential side effects can include dizziness, nausea, and pain [7].
Why would a doctor prescribe Xarelto?
Xarelto is prescribed to prevent and treat blood clots. It is commonly used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent DVT and PE in certain patients who have undergone hip or knee replacement surgery [8].
How does Xarelto work?
Xarelto works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade. By blocking Factor Xa, rivaroxaban reduces the formation of thrombin, which is essential for the development of blood clots [8].
What clinical data supports Xarelto's use?
Clinical trials, such as the ROCKET AF study for atrial fibrillation and the EINSTEIN trials for DVT and PE, have demonstrated the efficacy and safety of Xarelto in its approved indications [8].
Are there patient concerns about Xarelto?
Patient concerns often revolve around the risk of bleeding, managing side effects, and understanding the medication's role in their treatment plan. Discussions with healthcare providers are crucial for addressing individual patient concerns [7].
What is the difference between Xarelto and Eliquis?
While both Xarelto (rivaroxaban) and Eliquis (apixaban) are DOACs used for similar indications, they differ in their specific mechanisms of inhibition within the coagulation pathway and in their pharmacokinetic profiles. These differences can influence prescribing decisions based on patient factors and potential drug interactions. Eliquis is generally considered to have a lower risk of bleeding in some patient populations compared to Xarelto [6].
---
Sources:
[1] https://www.janssen.com/
[2] https://www.bayer.com/
[3] https://www.drugs.com/xarelto.html
[4] https://drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/drug/rivaroxaban/patent
[6] https://www.nhs.uk/medicines/rivaroxaban/
[7] https://www.rxlist.com/xarelto-side-effects-drug-center.htm
[8] https://www.xarelto.com/